Dupilumab - CISMeF

Preferred Label : Dupilumab;

NCIt definition : A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.;

UNII : 420K487FSG;

CAS number : 1190264-60-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1190264-60-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Dupixent;

Molecule name : REGN 668; SAR 231893; REGN-668; SAR-231893;

Details

Origin ID

C162455;

UMLS CUI

C3660996;

Automatic exact mappings (from CISMeF team)
- Dupilumab [ICD-11 Extension code]
Currated CISMeF NLP mapping
- Dupilumab [LOINC component]
- Dupilumab [Anticorps monoclonal]
- Dupilumab (substance) [SNOMED CT concept]
- dupilumab [MeSH concept]
- dupilumab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing dupilumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Dupilumab [LOINC component]
- Dupilumab (substance) [SNOMED CT concept]
- Product containing dupilumab (medicinal product) [SNOMED CT concept]
- dupilumab [ATC Code]
- dupilumab [MeSH Supplementary Concept]
- dupilumab [MeSH concept]
Validated automatic mappings to BTNT
- dupilumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
has_target
- Interleukin-4 Receptor Subunit Alpha [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients